Table 2 Results of inverse probability in the unweighted and weighted cohort
Unweighted cohort | Weighted cohort | |||||
|---|---|---|---|---|---|---|
Thrombolysis | Control | Thrombolysis | Control | Risk differences | ||
Outcomes | (n = 432) | (n = 788) | (n = 433) | (n = 787) | (95% CI) | P-value |
Primary outcome | ||||||
In-hospital mortality, n (%) | 225 (52) | 477 (61) | 240 (55) | 459 (58) | − 3.0 (− 9.6 to 3.5) | 0.36 |
Secondary outcomes | ||||||
Favorable neurological outcomes, n (%) | 182 (42) | 261 (33) | 170 (39) | 277 (35) | 4.0 (− 2.3 to 10.3) | 0.21 |
Length of hospital stay, days, mean (SD) | 29 (70) | 23 (32) | 27 (63) | 23 (32) | 3.9 (− 2.0 to 9.8) | 0.20 |
Length of VA-ECMO, days, mean (SD) | 3 (3) | 3 (4) | 3 (3) | 3 (4) | − 0.3 (− 0.7 to 0.2) | 0.21 |
Total hospitalization cost, × 103 dollars, mean (SD) | 30 (26) | 27 (21) | 30 (26) | 27 (21) | 2.9 (− 0.2 to 6.0) | 0.07 |
Major bleeding in a critical area or organ, n (%) | 17 (4) | 22 (3) | 23 (5) | 21 (3) | 2.6 (− 0.2 to 5.5) | 0.07 |
Intracranial bleeding, n (%) | 6 (1) | 9 (1) | 10 (2) | 9 (1) | 1.3 (− 0.9 to 3.5) | 0.26 |
Blood transfusions, ml, mean (SD) | ||||||
Red blood cells | 2829 (2651) | 2580 (2733) | 2880 (2761) | 2637 (2803) | 244 (− 140 to 627) | 0.21 |
Fresh-frozen plasma | 1413 (2155) | 1395 (1977) | 1545 (2417) | 1410 (2017) | 136 (− 207 to 479) | 0.44 |
Platelet concentrate | 254 (521) | 290 (540) | 272 (588) | 297 (553) | − 26 (− 107 to 56) | 0.54 |